comparemela.com

Latest Breaking News On - புற்றுநோய் ஆராய்ச்சி தொழில்நுட்பம் - Page 2 : comparemela.com

Macomics Ltd: Macomics, the Macrophage-based Drug Discovery company, secures £4 24m expansion financing, and appoints CEO, CSO and VP Immunology

(0) Follow-on investment, led by Epidarex Capital, closes at £4.24m, following initial £3.2m Seed round in 2020; Caribou Property joins as new investor Management appointments expand leadership team: Dr Steve Myatt, ex Azeria Therapeutics, to Chief Executive Officer; Dr Carola Ries, ex Roche, to Chief Scientific Officer; Co-founder Dr Luca Cassetta to move from his academic role at Edinburgh University to join as full-time VP Immunology Funds will accelerate macrophage-based therapeutics R&D portfolio and target discovery capability; expansion of facilities in Edinburgh and Cambridge Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, announces today that it has closed a follow-on financing of £4.24 million from its 2020 Seed round, bringing the total amount raised to £7.44m.

Edinburgh drug discovery accelerator targets fresh investment as new director named

Edinburgh drug discovery accelerator targets fresh investment as new director named
scotsman.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scotsman.com Daily Mail and Mail on Sunday newspapers.

CatalYm Appoints Industry Leader Dr Phil L Huillier as Chief Executive Officer

Share: MUNICH, Germany, May 04, 2021 (GLOBE NEWSWIRE) CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the appointment of Dr. Phil L Huillier as Chief Executive Officer (CEO), effective May 17, 2021. Dr. Phil L Huillier brings over two decades of experience in executive leadership positions in the pharmaceutical and biotechnology industries, with an outstanding track record of success in the commercial development of businesses and partnerships. His experience reflects an international career in business, science, and academia. Dr. Phil L Huillier joins CatalYm from a position as Head of the European Innovation Hub & Business Development at MSD (known as Merck & Co. in North America). In this position he was an active member of MSD global Business Development and Licensing Leadership as well leading a team of scientific and business development professionals that were focused on the identification, evaluation and development of

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.